| 排名 | 分析师 | 机构 | 行业 | 年度收益率 | 6个月收益率 | 3个月收益率 | 正收益比例 | 成分股数量 | 历史最大跌幅 | 更新日期 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 李安飞 | 广发证券 | 医药生物 | 48.11% | 40.67% | 44.37% | -2.86% | 1 | -56.96% | 2025-04-28 |
| 2 | 刘浩 | 华创证券 | 医药生物 | 48.10% | 37.34% | 29.33% | 29.41% | 2 | -47.33% | 2025-05-27 |
| 3 | 韩世通 | 中信证券 | 医药生物 | 48.09% | 46.35% | 38.83% | -2.04% | 6 | -63.25% | 2025-08-12 |
| 4 | 韩世通 | 中信证券 | 医药生物 | 48.08% | 13.46% | 36.14% | -2.04% | 6 | -63.25% | 2025-08-04 |
| 5 | 仰佳佳 | 申万宏源 | 医药生物 | 48.01% | 48.75% | 44.66% | 23.08% | 1 | -37.64% | 2025-06-12 |
| 6 | 李安飞 | 广发证券 | 医药生物 | 47.98% | 41.83% | 43.06% | -2.86% | 1 | -56.96% | 2025-04-24 |
| 7 | 张林晚 | 上海证券 | 医药生物 | 47.97% | 47.42% | 29.16% | -100.00% | 1 | -18.93% | 2025-08-13 |
| 8 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 47.75% | 48.89% | 40.45% | 12.50% | 7 | -27.10% | 2025-05-14 |
| 9 | 刘浩 | 华创证券 | 医药生物 | 47.74% | 46.68% | 48.07% | 29.41% | 1 | -47.33% | 2025-04-14 |
| 10 | 胡博新 | 华鑫证券 | 医药生物 | 47.67% | 46.49% | 35.36% | -6.32% | 5 | -51.98% | 2025-08-20 |
| 11 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 47.67% | 42.56% | 43.93% | 12.50% | 6 | -27.10% | 2025-05-12 |
| 12 | 胡博新 | 华鑫证券 | 医药生物 | 47.66% | 44.84% | 53.11% | -6.32% | 5 | -51.98% | 2025-08-15 |
| 13 | 王道 | 申万宏源 | 医药生物 | 47.62% | 48.32% | 49.09% | 33.33% | 4 | -42.73% | 2025-08-13 |
| 14 | 赵海春 | 国金证券 | 医药生物 | 47.59% | 54.10% | 58.00% | -25.00% | 2 | -61.07% | 2025-07-08 |
| 15 | 胡博新 | 华鑫证券 | 医药生物 | 47.48% | 52.06% | 48.73% | -6.32% | 3 | -51.98% | 2025-07-29 |
| 16 | 胡博新 | 华鑫证券 | 医药生物 | 47.48% | 48.95% | 49.14% | -6.32% | 4 | -51.98% | 2025-08-13 |
| 17 | 赵海春 | 国金证券 | 医药生物 | 47.33% | 52.41% | 54.65% | -25.00% | 2 | -61.07% | 2025-07-25 |
| 18 | 夏禹 | 国联民生 | 医药生物 | 47.29% | 41.44% | 34.24% | 20.00% | 7 | -52.01% | 2025-05-29 |
| 19 | 周豫 | 太平洋 | 医药生物 | 47.17% | 52.84% | 34.07% | 21.21% | 23 | -55.62% | 2025-08-01 |
| 20 | 周豫 | 太平洋 | 医药生物 | 47.06% | 47.84% | 36.31% | 21.21% | 23 | -55.62% | 2025-08-12 |